Reimagining ADC Design Through Enzymatic Conjugation: Enabling Site-Specific & Dual-Payload ADCs
- Analyze how GlycOBI® is a glycan site-specific conjugation platform enabling programmable DAR control, highlighting how precise glycan engineering supports homogeneous ADCs and tunable drug loading
- Assess how linker design and DAR tuning are key determinants of ADC stability and pharmacokinetics, with mechanistic insights into how linker architecture and DAR optimization jointly influence circulation stability and exposure
- Outline dual-payload ADC design principles, including the impact of distinct conjugation sites and payload release efficiencies, and a case study illustrating the rational design of a bispecific dual-payload ADC to overcome resistance mechanisms